Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代碼JUNS
公司名稱Jupiter Neurosciences Inc
上市日期Dec 03, 2024
CEORosen (Christer)
員工數量4
證券類型Ordinary Share
年結日Dec 03
公司地址1001 North US HWY 1, Suite 504
城市PALM BEACH GARDENS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33477
電話15614066154
網址https://jupiterneurosciences.com/
公司代碼JUNS
上市日期Dec 03, 2024
CEORosen (Christer)